Skip to main content

Plasma levels of perphenazine related to clinical effect and extrapyramidal side-effects

  • Chapter
Clinical Pharmacology in Psychiatry

Abstract

Many investigators have attempted to evaluate a correlation between the therapeutic effect and the plasma concentration of neuroleptic drugs (Buyze et al., 1973; Davis et al., 1974; Mjørndal and Oreland, 1971; Wiles and Franklin, 1978). Unfortunately, simultaneous registration of the degree of side-effects is often lacking. However, clinical experience shows that development of side-effects of neuroleptic drugs, especially extrapyramidal reactions, may have such substantial negative influence on the effort of resocialization that the total situation remains unsatisfactory in spite of amelioration of the psychotic symptoms (Bolvig Hansen et al., 1981). Therefore, it is of the utmost importance to handle neuroleptics in a way which gives maximal therapeutic effect with a minimum of side-effects.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Bolvig Hansen, L. and Larsen, N.-E. (1977). Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment. Psychopharmacology, 53, 127–30

    Article  Google Scholar 

  • Bolvig Hansen, L., Larsen, N.-E. and VestergÃĨrd, P. (1981). Plasma levels of perphenazine related to development of extrapyramidal side effects. Psychopharmacology, 74, 306–9

    Article  Google Scholar 

  • Buyze, G., Egberts, P.F.C., Muunsze, R.G. and Poslavska, A. (1973). Blood levels of thioridazine and some of its metabolites in psychiatric patients. A preliminary report. Psychiatr. Neurol. Neurochir., 76, 229–39

    CAS  PubMed  Google Scholar 

  • Davis, J.M., Janowski, D.S., Sekerti, H.J., Manier, D. and El-Youssef, M.K. (1974). The pharmacokinetics of butaperazine in serum. In Phenothiazines and Structurally Related Drugs (ed. I.S. Forrest, C.J. Carr and E. Usdin), Raven Press, New York, pp 433–43

    Google Scholar 

  • Mjørndal, T. and Oreland, L. (1971). Determination of thioxanthenes in plasma at therapeutic concentrations. Acta Pharmacol. Toxicol., 29, 295–302

    Article  Google Scholar 

  • Wiles, D.H. and Franklin, M. (1978). Radioimmunoassay for fluphenazine in human plasma. Br. J. Clin. Pharmacol., 5, 265–8

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Copyright information

Š 1983 The contributors

About this chapter

Cite this chapter

Hansen, L.B., Larsen, NE. (1983). Plasma levels of perphenazine related to clinical effect and extrapyramidal side-effects. In: Gram, L.F., Usdin, E., Dahl, S.G., Kragh-Sørensen, P., SjÃļqvist, F., Morselli, P.L. (eds) Clinical Pharmacology in Psychiatry. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-06671-1_16

Download citation

Publish with us

Policies and ethics